Vanguard Intl Div Apprec Idx ETF

Most Recent

  • uploads///rev eps trp
    Miscellaneous

    TRP’s Dividends: Key Drivers

    TransCanada Corporation (TRP) is an energy infrastructure company in North America. Its revenue grew 11% in both 2016 and 9M17.

    By Amanda Lawrence
  • uploads///rev eps enb
    Miscellaneous

    What Could Continue to Drive ENB’s Dividends

    Enbridge (ENB) is involved in energy transportation in the United States and Canada. Revenue grew 2% in 2016, compared to 25% in 9M17.

    By Amanda Lawrence
  • uploads///Alcon
    Company & Industry Overviews

    What to Expect for Novartis’s Subsidiary Alcon in 2018

    In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.4 billion, $1.5 billion, and $1.5 billion, respectively.

    By Daniel Collins
  • uploads///Crizan
    Company & Industry Overviews

    Novartis’s Crizanlizumab Demonstrates Positive Results in Trials

    In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    What Analysts Recommend for Roche in January 2018

    In December 2017, Roche and Ignyta entered a merger agreement where Roche will fully acquire Ignyta at a price of $27.0 per share in an all-cash transaction.

    By Daniel Collins
  • uploads///Perjeta
    Company & Industry Overviews

    Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018

    In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.

    By Daniel Collins
  • uploads///Victoza
    Company & Industry Overviews

    How Did Novo Nordisk’s Victoza and Saxendra Perform in 3Q17?

    In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///dy msft
    Tech & Comm Services

    Why Did MSFT’s Dividend Yield Fall in 2017?

    Microsoft’s (MSFT) revenue rose 12% in 1Q18.

    By Amanda Lawrence
  • uploads///DY DVN
    Energy & Utilities

    How Did DVN’s Dividend Cut Affect Its Dividend Yield?

    Devon Energy Corporation’s 56.0% dividend cut in 2016 was followed by a 43.0% cut in 2017.

    By Amanda Lawrence
  • uploads///Ophthalmology
    Company & Industry Overviews

    Inside Novartis’s Ophthalmology Drugs Now

    In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Actemra
    Company & Industry Overviews

    Roche’s Tarceva, Actemra, and Esbriet in 3Q17

    In 3Q17, Roche Holding’s (RHHBY) Actemra generated revenues of 485 million Swiss francs, which reflected ~13% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///REV EPS CAE
    Miscellaneous

    What Affected CAE’s Dividend Yield?

    CAE (CAE) is an international frontrunner in the delivery of training for the civil aviation, defense and security, and healthcare markets.

    By Amanda Lawrence
  • uploads///Rituxan and MabThera
    Company & Industry Overviews

    How Roche’s Rituxan and Acterma Are Positioned after 1H17

    In the first half of 2017, Roche’s (RHHBY) Rituxan/MabThera reported revenues of CHF 3.8 billion, which is a 3.0% rise on a YoY basis.

    By Daniel Collins
  • uploads///Esbriet revenues
    Company & Industry Overviews

    Esbriet Could Boost Roche’s Revenue Growth in 2H17

    In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.

    By Daniel Collins
  • uploads///Victoza revenues
    Company & Industry Overviews

    How Is Novo Nordisk’s Victoza Positioned after 2Q17?

    In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///HCN DIV
    Miscellaneous

    Welltower’s Dividend Yield Falls despite Higher Dividend

    Revenue and earnings In this part, we’ll look at Welltower (HCN), a US healthcare REIT. Welltower’s revenue growth slowed from 15% in 2015 to 11% in 2016. The growth was driven by all of its segments, through rental income, resident fees and services, interest income, and other income. Its operating costs and other expenses (including interest expenses) […]

    By Amanda Lawrence
  • uploads///Teva Womens health
    Company & Industry Overviews

    Behind TEVA’s Women’s Health Products after 1H17

    In 1H17, Teva Pharmaceutical’s (TEVA) women’s health business reported revenues of ~$239 million, or ~5% higher YoY (year-over-year).

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Fresenius Medical Care Is a Global Leader in the Dialysis Segment

    In addition to selling dialysis products, Fresenius Medical Care also offers dialysis treatment and associated laboratory services to patients through its network of 3,690 clinics.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Could SEG101 Revolutionize the Treatment for Sickle Cell Disease?

    Novartis (NVS) is currently involved in developing its investigational therapy SEG101 for sickle cell disease.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis Aims to Turn Around Its Surgical Business in 2017

    In 2016, the surgical business of Alcon, Novartis’s (NVS) Consumables segment, witnessed a solid demand trend.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Could Boost Medicare Demand for Novartis’s Entresto?

    If Novartis manages to further improve access to Entresto in 2017, it could have a favorable impact on the company’s stock and the Vanguard International Dividend Appreciation ETF (VIGI).

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.